Dramatic response to crizotinib in a breast cancer patient with ALK gene rearrangement
Küçük Resim Yok
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Lippincott Williams & Wilkins
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3-5% of non-small-cell lung cancer (NSCLC), while it was 0.2% in NSCLC tumors. Due to its low frequency, it is extremely challenging to conduct randomized clinical trials of ALK-targeted therapies in NSCLC tumors. In the present case, we describe the first reported case of triple-negative breast cancer (TNBC) harboring the ALK fusion mutation that responded to ALK-targeted therapy after progression with two lines of chemotherapy. Searching for ALK gene rearrangement or other fusion, especially in patients with chemotherapy-resistant TNBC, opens the door to new treatment strategies.
Açıklama
Anahtar Kelimeler
Alk Fusion, Breast Cancer, Crizotinib, Triple-Negative, Treatment, Cell Lung-Cancer
Kaynak
Anti-Cancer Drugs
WoS Q Değeri
Q3
Scopus Q Değeri
Q3
Cilt
33
Sayı
4
